Delving into the Latest Updates on Dimebutic acid with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Target

β-globin

Action

stimulants

Mechanism

β-globin stimulants(Hemoglobin beta chain stimulants)

Therapeutic Areas

Congenital DisordersHemic and Lymphatic DiseasesOther Diseases

Active Indication-

Inactive Indication

Anemia, Sickle CellBeta-ThalassemiaThalassemia

Originator Organization

Boston University

Active Organization-

Inactive Organization

HemaQuest Pharmaceuticals, Inc.

Boston University

License Organization-

Drug Highest PhaseDiscontinuedPhase 2

First Approval Date-

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC6H12NaO2

InChIKeyQHLWRCHRKPPHNM-UHFFFAOYSA-N

CAS Registry3934-02-9

View All Structures (2)

Beta thalassemia intermedia syndromes are genetic anemias caused by mutations which reduce production of beta globin, a major component of adult hemoglobin A, the protein which delivers oxygen throughout the body. Patients suffer from poor growth, fatigue, heart failure, endocrine deficiencies, and eventually, many require chronic blood transfusions. There is no approved therapeutic for the deficiency of beta globin chains in beta thalassemia.
This trial will study an oral therapeutic which stimulates production of fetal globin, an alternate type which is produced by all humans, but is normally switched off in infancy. This type of globin can compensate for the missing protein in beta thalassemia.

Start Date01 May 2012

Sponsor / Collaborator

Boston University

[+1]

NCT01322269

/ CompletedPhase 2

A Randomized, Open-Label, Multi-Dose Study of HQK-1001 in Subjects With Sickle Cell Disease

The purpose of this study is to evaluate the safety and tolerability of three dose levels of HQK-1001 administered once daily for 26 weeks in subjects with sickle cell disease.

Start Date01 Apr 2011

Sponsor / Collaborator

HemaQuest Pharmaceuticals, Inc.

100 Clinical Results associated with Dimebutic acid

Login to view more data

100 Translational Medicine associated with Dimebutic acid

Login to view more data

100 Patents (Medical) associated with Dimebutic acid

Login to view more data

577

Literatures (Medical) associated with Dimebutic acid

28 Mar 2025·Organic Letters

Palladium-Catalyzed Directed Alkenylation of Alkyl Amides with Unactivated Alkenes: Access to γ-Alkenyl γ-Lactams

Article

Author: Barman, Madhab ; Mandal, Santu ; Punniyamurthy, Tharmalingam ; Nanjegowda, Maniya V.

Pd(II)-catalyzed cascade C(sp³)-H alkenylation and cyclization of alkyl amides with readily accessible unactivated alkenes have been accomplished. Alkenylation and subsequent intramolecular cyclization empowered the formation of functionalized γ-lactams, which present as an active core of several bioactive and natural products. The use of catalytic Cu(OAc)₂ along with molecular oxygen as the oxidant, a 2-chloropyridine ligand, site selectivity, the substrate scope, and gram-scale synthesis are important practical features.

14 Mar 2025·The Journal of Organic Chemistry

Decarboxylative Alkylation of Morita–Baylis–Hillman Acetates with Aliphatic Acids via Photochemical Iron-Mediated Ligand-to-Metal Charge Transfer

Article

Author: Jing, Lin-Hai ; Mei, Yu-Tong ; Guo, Zi-Yi ; Zhang, Hui ; Zheng, Yu-Xuan ; Shi, Ming-Song ; Hou, Qiu-Yao ; Yang, Dan ; Cheng, De-Jun

Carboxylic acids are bench-stable and readily available chemical feedstocks that function as optimal and fundamental synthetic platforms for the construction of C(sp³)-C(sp³) bonds via decarboxylation processes. We present a novel and practical protocol for the decarboxylative alkylation of Morita-Baylis-Hillman acetates with various carboxylic acids via a photoinduced iron-mediated ligand-to-metal charge transfer (LMCT) process under redox-neutral conditions. This method exhibits remarkable tolerance to a wide array of carboxylic acids, including primary, secondary, and tertiary carboxylic acids, obviating the requirement for preactivated radical precursors. The preliminary mechanistic analyses indicate that a radical pathway is involved in this catalytic transformation.

07 Mar 2025·Organic Letters

Synthesis of γ-Lactams via Palladium-Catalyzed C(sp³)–H Bond Activation of Alkyl Sulfonamides with Substituted Alkenes

Article

Author: Dutta, Ananya ; Jeganmohan, Masilamani

A methodology for the γ-butyrolactam scaffolds via ligand-enabled C(sp³)-H bond functionalization of sulfonamides with olefins has been demonstrated. The protocol has been found to be compatible with several activated and unactivated olefins, and the desired lactams were formed in excellent yields. A plausible mechanism has been described to account for the desired lactamization reaction as well as supported by mechanistic investigation including a ¹H NMR study and isolation of a palladacycle intermediate.

1

News (Medical) associated with Dimebutic acid

09 Dec 2008

·www.biospace.com

HemaQuest Announces Clinical Progress on New Sickle Cell Anemia Drug

SAN FRANCISCO, CA--(Marketwire - December 09, 2008) - HemaQuest Pharmaceuticals announced today the successful completion of Phase 1 clinical trials of HQK-1001, an orally-administered therapeutic which the company is developing to treat hemoglobin disorders, including sickle cell anemia and beta thalassemia. The company presented the results at the annual meeting of the American Society of Hematology in San Francisco.

100 Deals associated with Dimebutic acid

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Beta-Thalassemia	Phase 2	Lebanon	HemaQuest Pharmaceuticals, Inc.	01 May 2012
Anemia, Sickle Cell	Phase 2	Lebanon	HemaQuest Pharmaceuticals, Inc.	01 Apr 2011
Anemia, Sickle Cell	Phase 2	United States	HemaQuest Pharmaceuticals, Inc.	01 Apr 2011
Anemia, Sickle Cell	Phase 2	Canada	HemaQuest Pharmaceuticals, Inc.	01 Apr 2011
Anemia, Sickle Cell	Phase 2	Jamaica	HemaQuest Pharmaceuticals, Inc.	01 Apr 2011
Anemia, Sickle Cell	Phase 2	Egypt	HemaQuest Pharmaceuticals, Inc.	01 Apr 2011
Thalassemia	Phase 2	-	Boston University	-

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01601340 (Pubmed \| Am J Hematol)	Phase 2	Anemia, Sickle Cell	76	HQK-1001	noxnpwoddo(dilxdvonky) = The most common adverse events in the HQK-1001 group, usually graded as mild or moderate, consisted of abdominal pain qbumdyfymb (tmmwwzpwcz ) View more	Negative	01 Jul 2014
				Placebo